CRP and diabetes mellitus: In the pooled analysis of the two placebo-controlled studies of sarilumab + MTX/csDMARDs, treatment by diabetes status interaction tests were not significant for ACR20 (p = 0.224) or for change from baseline in HAQ-DI (p = 0.475), DAS28-CRP (p = 0.110) or CDAI (p = 0.597).